Pantocid Injection (Pantoprazole Sodium Sesquihydrate)

Adult dosage

If oral administration of pantoprazole is inappropriate, reconstitute 1 vial of this drug (equivalent to 40 mg of pantoprazole) with 10 mL of normal saline and administer by direct intravenous injection, or mix this solution with 100 mL of normal saline or 5 % dextrose solution and administer intravenously over 2∼15 minutes. As soon as oral administration becomes possible, discontinue intravenous pantoprazole and switch to oral pantoprazole 40 mg. 1. Duodenal ulcers, gastric ulcers, moderate ∼ severe reflux esophagitis Administer 1 vial of this drug (equivalent to 40 mg of pantoprazole) by intravenous injection once daily. 2. Zollinger-Ellison syndrome and other pathological gastric acid hypersecretory conditions - Start with an initial dose of 80 mg per day, then increase or decrease the dose according to measurements of gastric acid secretion. - Doses of 80 mg or more should be divided into 2 doses per day. - Temporary increases to 160 mg or more are possible, but should be used only for as long as necessary to achieve adequate acid control. - When rapid acid control is needed, an initial dose of 2 × 80 mg reduced acid output to the target range (< 10 mEq/h) within one hour in most patients. ◯ In patients with severe hepatic impairment, the daily dose should be reduced to 20 mg of pantoprazole. ◯ In older adults or patients with renal impairment, the daily dose should not exceed 40 mg of pantoprazole.

This drug should not be administered to certain patients. It should not be used in patients with hypersensitivity to this drug or its components, or those with a history of allergic reactions, and those currently taking certain antiviral medications. Various adverse reactions may occur while using this medication. Symptoms such as indigestion, diarrhea, headache, dizziness, skin rash, liver function abnormalities, myalgia, and depression have been reported, so if any abnormal symptoms occur, immediate consultation with healthcare professionals is necessary. Regular tests to check liver function and electrolyte status are important during long-term use of this drug. In particular, long-term use (more than 1 year) can lead to electrolyte imbalances such as hypomagnesemia, so caution is warranted. Since this drug suppresses gastric acid secretion, it may increase the risk of bacterial overgrowth in the gastrointestinal tract, so if diarrhea persists, testing for Clostridium difficile infection should be conducted. Dizziness or vision disturbances may occur, so caution is advised during activities that require alertness, such as driving or operating machinery. It is best to avoid use during the first trimester of pregnancy, and breastfeeding women should not take this drug. There is insufficient experience with this drug in children and adolescents under 18 years of age, so its use is not recommended. This drug may interact with other medications, so if you are taking any other medications, be sure to inform your healthcare provider. There is no specific antidote for overdose; appropriate treatment based on symptoms should be received. The prepared solution of this drug should be used within 12 hours prior to administration, and any solution that is discolored or cloudy should not be used. Long-term use of this drug may increase the risk of gastric fundic polyps, so it is advisable to use the minimum effective dose for the shortest duration necessary.

Anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, urticaria, agranulocytosis, leukopenia, thrombocytopenia, pancytopenia, epigastric pain, diarrhea, constipation, abdominal distension, dyspepsia, gastric polyp, nausea, vomiting, dry mouth, rhinitis, injection site reaction, thrombophlebitis at the injection site, elevated body temperature, peripheral edema, fever, elevated bilirubin, liver failure, jaundice, hepatocellular injury, elevated liver enzymes, arthralgia, myalgia, rhabdomyolysis, bone fractures, headache, dizziness, visual disturbances, taste disturbances, insomnia, sleep disturbances, depression, hallucinations, disorientation, confusion, interstitial nephritis, pruritus, skin redness, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, photosensitivity reactions, gynecomastia, hyperlipidemia, increased lipids, weight change, hyponatremia, hypomagnesemia, elevated CK, anterior ischemic optic neuropathy, pancreatitis, confusion, decreased mobility, speech disorders, increased salivation, vertigo, tinnitus, hypocalcemia, hypokalemia, Clostridium difficile-associated diarrhea, paresthesia, DRESS syndrome, microscopic colitis, systemic lupus erythematosus, discoid lupus erythematosus, cytopenia, increased serum chromogranin A levels

This drug is sensitive to light, so it should be stored in a container that blocks light. Additionally, it is important to store it at a cool temperature below 25 degrees Celsius to maintain the drug's effectiveness.

Appearance

This drug is a colorless transparent vial containing a white to almost white dry powder.

Package unit

46.1 mg/vial [(1 vial)]